Hoffmann-La Roche Limited

Hoffmann-La Roche Limited is a biotechnology company that discovers and develops medicines for people with serious and life-threatening diseases. Its technical work spans biomedical research, drug discovery and development, biologics manufacturing and personalised medicine, with dedicated programmes in oncology and neuroscience. The company applies AI across R&D, including molecule discovery, and invests in state-of-the-art manufacturing facilities.

Founded in 1976, the company has operated for nearly 50 years and is a member of the Roche Group, working across the United States and globally. It has committed $50 billion to U.S. manufacturing and R&D investment. Its research record includes Genentech's transformational discovery of the first personalized (targeted) medicine for cancer and the first treatment for primary progressive multiple sclerosis.

The organisation describes a science-driven culture that draws on collaboration across the Roche Group. It has set out to level barriers to clinical trial participation, drive inclusive research and diversity in trials, and optimise health outcomes for all patients, alongside novel customer engagement strategies.